35120-18-4

Usage

Uses

Used in Pharmaceutical Synthesis:
1-BROMO-CYCLOBUTANECARBOXYLIC ACID ETHYL ESTER is used as a synthetic intermediate for the production of 1-aminocyclobutane carboxylic acid, which is a key component in the development of pharmaceuticals. Its role in the synthesis process is crucial for creating new and innovative medications.
Used in Chemical Industry:
In the chemical industry, 1-BROMO-CYCLOBUTANECARBOXYLIC ACID ETHYL ESTER is used as a versatile building block for the creation of various chemical compounds. Its unique structure allows for further functionalization and modification, making it a valuable asset in the development of new materials and products.
Used in Research and Development:
1-BROMO-CYCLOBUTANECARBOXYLIC ACID ETHYL ESTER is also utilized in research and development settings, where it can be employed to study the properties and reactivity of similar compounds. This helps scientists and researchers gain a deeper understanding of the underlying chemistry and potentially discover new applications for this class of compounds.

InChI:InChI=1/C7H11BrO2/c1-2-10-6(9)7(8)4-3-5-7/h2-5H2,1H3

Upstream product

• 64-17-5 ethanol 
• 3721-95-7 Cyclobutanecarboxylic acid 
• 14924-53-9 ethyl cyclobutylcarboxylate 

Downstream Products

• 113239-54-6 1-(4-Butyryl-2,3-dichloro-phenoxy)-cyclobutanecarboxylic acid ethyl ester 
• 784148-57-8 ethyl 1-(3-iodophenoxy)cyclobutanecarboxylate 
• 845252-89-3 N-benzyl-N-(but-3-ynyl)-1-cyclobutene-1-carboxamide 
• 845252-91-7 N-benzyl-N-(pent-3-ynyl)-1-cyclobutene-1-carboxamide 
• 845252-82-6 N-(but-3-ynyl)-N-(cyclobut-1-enylmethyl)-p-toluenesulfonamide 
• 845252-92-8 N-benzyl-N-(4-phenylbut-3-ynyl)-1-cyclobutene-1-carboxamide 
• 1027186-62-4 N-(cyclobut-1-enylmethyl)-N-(5-hydroxypent-3-ynyl)-p-toluenesulfonamide 
• 1026347-84-1 methyl 5-[N-(cyclobut-1-enylmethyl)-N-(p-toluenesulfonyl)amino]pent-2-ynoate 
• 845252-86-0 ethyl 2-[N-(cyclobut-1-enylmethyl)-N-(p-toluenesulfonyl)amino]pent-4-ynoate 
• 845252-84-8 5-[N-(cyclobut-1-enylmethyl)-N-(p-toluenesulfonyl)amino]pent-2-ynyl acetate 
• 845252-94-0 N-benzyl-N-(4-(naphthalen-1-yl)but-3-ynyl)-1-cyclobutene-1-carboxamide 
• 845252-93-9 ethyl 4-{4-[N-benzyl-N-(cyclobut-1-enecarbonyl)amino]but-1-ynyl}benzoate 
• 113239-53-5 1-(2,3-dichloro-4-butyrylphenoxy)cyclobutane-1-carboxylic acid 
• 348640-44-8 1-{6-Methoxy-1-methyl-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-1H-indol-5-yloxy}-cyclobutanecarboxylic Acid Ethyl Ester 

Relevant academic research and scientific papers

Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates

Disulfide bonds could be valuable linkers for a variety of therapeutic applications requiring tunable cleavage between two parts of a molecule (e.g., antibody-drug conjugates). The in vitro linker immolation of β-mercaptoethyl-carbamate disulfides and DNA alkylation properties of associated payloads were investigated to understand the determinant of cell killing potency of anti-CD22 linked pyrrolobenzodiazepine (PBD-dimer) conjugates. Efficient immolation and release of a PBD-dimer with strong DNA alkylation properties were observed following disulfide cleavage of methyl- and cyclobutyl-substituted disulfide linkers. However, the analogous cyclopropyl-containing linker did not immolate, and the associated thiol-containing product was a poor DNA alkylator. As predicted from these in vitro assessments, the related anti-CD22 ADCs showed different target-dependent cell killing activities in WSU-DLCL2 and BJAB cell lines. These results demonstrate how the in vitro immolation models can be used to help design efficacious ADCs.

SULFONYLCYCLOALKYL CARBOXAMIDE COMPOUNDS AS TRPA1 MODULATORS

The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Design, synthesis, and conformational analysis of 3-: Cyclo -butylcarbamoyl hydantoins as novel hydrogen bond driven universal peptidomimetics

A collection of systematically substituted 3-cyclo-butylcarbamoyl hydantoins was synthesized by a regioselective multicomponent domino process followed by easy coupling reactions. Calculations, NMR studies and X-ray analysis show that these scaffolds are able to project their side chains similar to common secondary structures, such as the α-helix and β-turn, with favourable enthalpic and entropic profiles.

PROCESS FOR THE PREPARATION OF ORGANIC BROMIDES

The present invention provides a process for the preparation of organic bromides, by a radical bromodecarboxylation of carboxylic acids with a bromoisocyanurate.

HINDERED DISULFIDE DRUG CONJUGATES

The invention relates generally to disulfide drug conjugates wherein a linker comprising a sulfur-bearing carbon atom substituted with at least one hydrocarbyl or substituted hydrocarbyl is conjugated by a disulfide bond to a cysteine sulfur atom of a targeting carrier, and wherein the linker is further conjugated to a drug moiety. The invention further relates to activated linker-drug conjugates suitable for conjugation to a targeting carrier by a disulfide bond. The invention further relates to methods for preparing hindered disulfide drug conjugates.

Cu-Catalyzed Alkynylation of Unactivated C(sp3)-X Bonds with Terminal Alkynes through Directing Strategy

In this letter, we report an efficient and concise protocol for Cu-catalyzed cross-coupling of unactivated alkyl halides/peusudohalides with terminal alkynes to afford internal alkynes with the assistance of various amides as directing groups. Different alkyl halides/pseudohalides exhibited excellent reactivities, and the inactivated alkyl chlorides and sulfonates showed better reactivity than bromides/iodides. This is the first successful example to apply alkyl chlorides and sulfonates directly in cross-coupling with terminal alkynes in the absence of any additives. A Cu catalyst was found to be more effective than other transition metal catalysts. This reaction also exhibited a broad substrate scope with respect to terminal alkynes.

Synthesis of chiral cyclobutanes via rhodium/diene-catalyzed asymmetric 1,4-addition: A dramatic ligand effect on the diastereoselectivity

A highly diastereo- and enantioselective rhodium-catalyzed arylation of cyclobutenes for the efficient synthesis of chiral cyclobutanes has been developed. Chiral diene ligands exhibited excellent capability for the reaction diastereoselectivity control.

NOVEL COMPOUNDS

Disclosed are novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

Synthesis of the 1-monoester of 2-ketoalkanedioic acids, for example, octyl α-ketoglutarate

Oxidative cleavage of cycloalkene-1-carboxylates, made from the corresponding carboxylic acids, and subsequent oxidation of the resulting ketoaldehyde afforded the important 1-monoesters of 2-ketoalkanedioic acids. Thus ozonolysis of octyl cyclobutene-1-carboxylate followed by sodium chlorite oxidation afforded the 1-monooctyl 2-ketoglutarate. This is a cell-permeable prodrug form of α-ketoglutarate, an important intermediate in the tricarboxylic acid (TCA, Krebs) cycle and a promising therapeutic agent in its own right.

7 2-(Aminocarbonylalkoxyimino)acetamido! derivatives of cephalosporin

Cephalosporin antibiotics in which the 7β-acylamido group has the structure STR1 (WHERE R is phenyl, thienyl or furyl; Ra and Rb are each selected from hydrogen, C1-4 alkyl, C2-4 alkenyl, C3-7 cycloalkyl, phenyl, naphthyl, thienyl, furyl, carboxy, C2-5 alkoxycarbonyl, aminocarbonyl, N-substituted aminocarbonyl and cyano, or Ra and Rb together with the carbon atom to which they are attached form a C3-7 cycloalkylidene or cycloalkenylidene group; Rc is hydrogen or C1-4 alkyl; and m and n are each 0 or 1 such that the sum of m and n is 0 or 1) exhibit broad spectrum antibiotic activity characterized by particularly high activity against gram negative microorganisms, including those which produce β-lactamases. The compounds, which are syn isomers or exist as mixtures of syn and anti isomers containing at least 90% of the syn isomer, have particularly good activity against Proteus organisms including indole positive strains and, especially when both Ra and Rb are other than hydrogen, against Pseudomonas organisms.